7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori

Inclusion criteria

• Age 18-70 years, no gender restrictions;
• Patients with H. pylori infection confirmed by 13C/14C-urea breath test ;
• No prior history of H. pylori eradication therapy;

Exclusion criteria

• Patients allergic to study medications (vonoprazan fumarate, amoxicillin);
• Patients with active qastrointestinal bleeding,;
• Patients undergone or scheduled to undergo surgery within 1 month prior to randomization or during the study period that may affect gastric acid secretion (e.g., gastric surgery, vagotomy, or craniotomy);
• Patients underlying severe medical conditions deemed by the investigator to potentially confound study results or compromise subject safety, such as: hepatic impairment (ALT or AST > 1.5 times the upper limit of normal); renal impairment (Cr ≥ 2.0 mg/dL or eGFR < 50 mL/min/1.73 m²); immunosuppression; malignancy; severe central nervous system, cardiovascular, or respiratory disease;
• Patients with medication history of bismuth, antibiotics within 4 weeks, or proton pump inhibitors within 2 weeks;
• Patients with behaviors potentially increasing disease risk: history of chronic substance abuse or alcohol dependence within 12 months prior to screening;
• Patients planning pregnancy, currently pregnant, breastfeeding, or unwilling to use contraception during the trial period;
• Patients unable or unwilling to provide informed consent.